New data from 50,000 patients shows strong outcomes across complex metabolic conditions.
July 2026: For many Indians living with insulin resistance, Type 2 Diabetes, PCOS or hypothyroidism, losing weight can feel significantly harder than it should.
While conventional weight-loss advice often focuses on eating less and moving more, patients with underlying metabolic conditions frequently face biological barriers that make sustainable weight loss far more challenging. Yet new clinical outcomes data from Elevate Now, India’s largest data-backed metabolic health programme, suggests that meaningful results are possible even among these complex patient groups.
Drawing on insights from more than 50,000 patient journeys, Elevate Now’s latest Clinical Excellence Report found that patients achieved an average body weight reduction of 11.8% over 12 months, with the programme’s highest-performing patients exceeding 20% weight loss.
What makes these outcomes particularly noteworthy is the profile of the patients entering the programme.
According to the report, 83% of patients presented with insulin resistance, nearly two-thirds had elevated inflammation markers, 39.4% had dyslipidemia, 25.7% were prediabetic and more than one in five were already living with Type 2 Diabetes. Many also presented with conditions such as hypothyroidism, fatty liver disease, hypertension and PCOS.
Key Findings from Elevate Now’s Clinical Outcomes Report
- 50,000+ patient journeys analysed
- 11.8% average weight loss at 12 months
- 20%+ weight loss among top-performing patients
- 83% of patients presented with insulin resistance
- 12.1% average weight loss among PCOS patients
- 11.45% average weight loss among Type 2 Diabetes patients
- 95,000+ consultations delivered
- 75,000+ blood tests processed
Despite these challenges, Elevate Now’s data shows consistent double-digit weight loss across major metabolic conditions. Patients with PCOS achieved an average weight loss of 12.1% at 12 months, while those with Type 2 Diabetes, hypothyroidism, fatty liver disease and hypertension recorded average reductions between 11% and 12%.
Among the programme’s highest-performing patients, weight loss ranged from 19% to 21% across cohorts—approaching outcomes traditionally associated with more intensive interventions.
The findings challenge the long-held perception that metabolic conditions inevitably limit a patient’s ability to achieve meaningful weight loss. Instead, they suggest that when underlying drivers such as insulin resistance, inflammation and hormonal dysfunction are identified and addressed, patients can achieve significant and sustainable results.
Commenting on the findings, Suryansh Kumar, Founder & CEO, Elevate Now, said: “Many patients come to us after years of struggling with their weight despite trying multiple diets, exercise plans and programmes. What we’ve consistently found is that the challenge is often biological, not behavioural. Conditions such as insulin resistance, inflammation and hormonal dysfunction can significantly impact outcomes if left unaddressed. At Elevate Now, we’re building a healthcare platform that helps patients understand and treat these underlying drivers so they can achieve sustainable improvements in both weight and overall metabolic health.”
Elevate Now combines medical consultations, diagnostics, personalised nutrition, fitness guidance and behavioural coaching to deliver clinically guided obesity care. Today, the company serves more than 50,000 patients across India and has delivered over 95,000 consultations while processing more than 75,000 blood tests, creating one of the country’s largest real-world metabolic health datasets.
As obesity and metabolic disorders continue to rise across India, the findings reinforce a growing shift in obesity care: success is not determined solely by willpower or calorie counting. Increasingly, sustainable outcomes depend on understanding the biological factors that drive weight gain and building treatment around them.
For patients living with insulin resistance, diabetes, PCOS, hypothyroidism and other metabolic conditions, Elevate Now’s latest data offers an encouraging message: even the most complex weight-loss journeys can produce meaningful results when the right clinical support is in place.
Syndicated press content is not written by ED Times
Read more
Why Are People Buying Taylor Swift’s Trash For Exorbitant Prices?
